NCT03773107: Phase 1/2: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib RRMM
Updated: Feb 10
Multiple Myeloma Research Consortium
NCT03773107: Phase 1/2: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
The primary objective of Phase I is to establish the maximum tolerated dose (MTD) of ruxolitinib in combination with carfilzomib and dexamethasone. The primary objective of phase II is to evaluate progression-free survival (PFS) at 4 months in multiple myeloma subjects who receive the combination treatment carfilzomib, dexamethasone, and ruxolitinib.
Sponsor
Wake Forest University Health Sciences
Collaborators
Incyte Corporation
Multiple Myeloma Research Consortium
Amgen
ClinicalTrials.gov Identifier: NCT03773107
Official Title: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Phase I/II Study of Carfilzomib, Ruxolitinib, and Low Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma
First Posted: December 12, 2018
Click here to see details on ClinicalTrials.gov
Drug: Carfilzomib
Drug: Ruxolitinib
Drug: Dexamethasone
Locations:
United States, Michigan
Karmanos Cancer Institute, Detroit, Michigan
United States, North Carolina
Levine Cancer Institute
Charlotte, North Carolina